Zollinger‑Ellison syndrome – refractory ulcer disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome – Refractory Ulcer Disease – Patient Guide

Zollinger‑Ellison Syndrome – Refractory Ulcer Disease

Overview

Zollinger‑Ellison syndrome (ZES) is a rare endocrine disorder in which one or more tumors (called gastrinomas) form in the pancreas or duodenum and secrete excessive amounts of the hormone gastrin. The high gastrin level overstimulates the stomach’s acid‑producing cells, leading to severe, acid‑related ulcer disease that does not respond to standard ulcer therapy—hence the term “refractory ulcer disease.”

  • Incidence: Approximately 1 in 100,000 people per year worldwide.1
  • Prevalence: About 0.5‑1 case per million population; slightly higher (≈2–3/100,000) in patients with multiple endocrine neoplasia type 1 (MEN‑1).2
  • Age & gender: Most patients are diagnosed between 30‑60 years of age; men and women are affected equally.

Because the ulcers can occur throughout the gastrointestinal (GI) tract—including the duodenum, jejunum, and even the esophagus—symptoms are often severe, recurrent, and resistant to proton‑pump inhibitors (PPIs) or H2‑blockers alone. Early recognition and targeted treatment are crucial to prevent life‑threatening complications.

Symptoms

Symptoms arise from two mechanisms: (1) hyperacidic environment causing ulcer disease, and (2) mass effect of the gastrinoma (if large). The most common presentation includes:

Gastro‑intestinal symptoms

  • Refractory peptic ulcer pain: Burning or gnawing epigastric pain that persists despite standard ulcer therapy.
  • Diarrhea: Occurs in 30‑50 % of patients due to acid inactivation of pancreatic enzymes and mucosal damage.
  • Steatorrhea (fatty stools): Malabsorption from pancreatic enzyme inactivation.
  • Vomiting: May be bilious if obstruction or severe ulceration is present.
  • Upper GI bleeding: Hematemesis or melena from ulcer erosion.
  • Weight loss: Result of malabsorption, chronic diarrhea, and reduced oral intake.
  • Recurrent ulcer disease: Ulcers can appear in atypical sites (jejunum, ileum, esophagus).

Systemic / hormonal symptoms

  • Abdominal fullness or a palpable mass: Large gastrinomas (>2 cm) may be felt.
  • Flushing, palpitations, or dizziness: Rarely occur if the tumor secretes other hormones.
  • Signs of MEN‑1: Hyperparathyroidism, pituitary tumors – important to ask about family history.

Causes and Risk Factors

Zollinger‑Ellison syndrome is almost always caused by a gastrin‑secreting neuroendocrine tumor.

Primary causes

  • Sporadic gastrinomas: ~70‑80 % of cases have no identifiable genetic link.
  • Multiple endocrine neoplasia type 1 (MEN‑1): ~20‑30 % of ZES patients have MEN‑1, an inherited mutation in the MEN1 tumor suppressor gene.

Risk factors

  • Family history of MEN‑1 or known MEN1 mutation.
  • Previous diagnosis of a pancreatic neuroendocrine tumor.
  • Chronic Helicobacter pylori infection does NOT cause ZES but may coexist and confound diagnosis.

Diagnosis

Because ZES mimics common ulcer disease, a high index of suspicion is needed when ulcers are refractory to therapy or when ulcers appear distal to the duodenum.

Step‑wise diagnostic approach

  1. Clinical suspicion: Recurrent or atypical ulcers, unexplained diarrhea, and high gastric acid output.
  2. Fasting serum gastrin level: Measured after overnight fast. Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially if gastric pH < 2.3
  3. Secretin stimulation test: Increments > 120 pg/mL after intravenous secretin strongly support ZES (useful when basal gastrin is modestly elevated).
  4. Imaging to locate gastrinoma:
    • Multiphasic contrast‑enhanced CT or MRI of the abdomen.
    • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – higher sensitivity for small lesions.
    • EUS (endoscopic ultrasound) for lesions < 1 cm.
  5. Endoscopy: Upper GI endoscopy confirms ulcer location, severity, and rules out other causes (e.g., H. pylori, malignancy).
  6. MEN‑1 screening: Serum calcium, PTH, prolactin, IGF‑1; genetic testing if family history present.

Diagnosis is confirmed when (1) fasting gastrin is markedly elevated, (2) gastric pH is low, and (3) a gastrinoma is visualized or functional testing is positive.

Treatment Options

Management of ZES requires two parallel goals: control of acid hypersecretion and treatment of the tumor.

Acid‑Suppressive Therapy

  • High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 60‑120 mg daily, or equivalent doses of esomeprazole, pantoprazole, etc. PPIs are the cornerstone and usually achieve near‑complete symptom control.4
  • Continuous infusion: In rare refractory cases, a PPI can be administered intravenously (e.g., pantoprazole 8 mg/h) while awaiting definitive therapy.
  • H2‑blockers: May be added for breakthrough symptoms but are far less effective than PPIs.

Definitive Tumor Management

  1. Surgical resection: Preferred for localized gastrinomas (< 2 cm) without metastatic spread. Options include enucleation or pancreaticoduodenectomy.
  2. Medical therapy for unresectable or metastatic disease:
    • Somatostatin analogs (octreotide, lanreotide) suppress gastrin release and may shrink tumors.
    • Targeted therapy (everolimus, sunitinib) for advanced neuroendocrine tumors.
    • Cytotoxic chemotherapy (streptozocin‑based regimens) in selected cases.
  3. Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE for patients with high somatostatin‑receptor expression.
  4. Liver-directed therapies: Radiofrequency ablation or embolization for hepatic metastases.

Lifestyle and Supportive Measures

  • Avoid NSAIDs, aspirin, and other ulcer‑aggravating medications.
  • Limit alcohol and caffeine, which stimulate acid production.
  • Small, frequent meals to reduce gastric workload.
  • Supplement fat‑soluble vitamins (A, D, E, K) if malabsorption is present.

Living with Zollinger‑Ellison syndrome – refractory ulcer disease

Long‑term management focuses on symptom control, monitoring for tumor progression, and maintaining nutritional health.

Daily Management Tips

  • Take PPIs exactly as prescribed: Most patients need them twice daily; do not skip doses.
  • Track symptoms: Keep a diary of pain, stool frequency, and any acid reflux. Note any breakthrough pain despite medication.
  • Regular follow‑up labs: Check fasting gastrin, vitamin B12, iron, and electrolytes every 6‑12 months.
  • Imaging surveillance: CT/MRI or somatostatin PET every 12‑24 months, or sooner if symptoms change.
  • Nutrition: Work with a dietitian to ensure adequate calories, protein, and micronutrients; consider pancreatic enzyme replacement if steatorrhea persists.
  • Vaccinations: If you receive somatostatin analogs or chemotherapy, stay up‑to‑date on flu and pneumococcal vaccines.

Psychosocial Support

Living with a chronic rare disease can be stressful. Joining patient groups (e.g., American Neuroendocrine Tumor Society) and seeking counseling can improve quality of life.

Prevention

Because ZES is primarily tumor‑driven, true primary prevention is limited. However, the following measures can reduce related complications:

  • Early detection in families with MEN‑1 through genetic counseling and routine screening.
  • Avoidance of chronic NSAID or high‑dose aspirin use, which could exacerbate ulcer formation.
  • Prompt treatment of H. pylori infection to eliminate another ulcer‑causing factor.

Complications

If untreated or inadequately controlled, ZES can lead to serious health issues:

  • Bleeding ulcers: Can cause anemia or life‑threatening hemorrhage.
  • Perforation: Full‑thickness ulcer can lead to peritonitis.
  • Gastrointestinal obstruction: From stenosis or tumor mass effect.
  • Severe malabsorption: Protein‑energy wasting, deficiencies of iron, calcium, and fat‑soluble vitamins.
  • Metastatic disease: Approx. 50‑60 % of gastrinomas have liver metastases at diagnosis; reduces survival if not treated.
  • Refractory diarrhea and electrolyte imbalance: Can lead to dehydration and renal dysfunction.

When to Seek Emergency Care

Go to the nearest emergency department or call emergency services (e.g., 911) immediately if you experience any of the following:
  • Sudden, severe abdominal pain that is unrelenting or worsens rapidly.
  • Vomiting of blood (bright red or coffee‑ground appearance) or black, tarry stools.
  • Signs of severe dehydration: dizziness, fainting, rapid heartbeat, or decreased urine output.
  • High‑fever (> 38.5 °C / 101 °F) accompanied by abdominal pain, suggesting perforation or infection.
  • Sudden onset of difficulty breathing or chest pain, which could signal a perforated ulcer causing sepsis.

Prompt treatment can be lifesaving.

Sources:

  1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. Link.
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome Fact Sheet.” 2022. Link.
  3. American College of Gastroenterology. “Clinical Guidelines for the Management of Gastric Acid‑Related Diseases.” 2021.
  4. Cleveland Clinic. “Zollinger‑Ellison syndrome treatment.” 2024. Link.
  5. World Health Organization. “Neuroendocrine Tumors: Guidelines.” 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References